#United States #New York #Actimab-A #Actinium Pharmaceuticals #NCI CRADA

Actinium Pharmaceuticals Participates in the 37th Annual Roth Conference

Actinium Pharmaceuticals, Inc., an innovative leader in the field of targeted radiotherapies, has announced its participation in the 37th Annual Roth Conference, which will take place from March 16 to 18, 2025. The company, traded on the NYSE AMERICAN under the ticker ATNM, will allow interested investors to meet with Actinium management for one-on-one discussions on March 17 and 18.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals is at the forefront of developing targeted radiotherapies that aim to significantly enhance patient outcomes. The company's flagship candidate, Actimab-A, is a treatment designed to target the CD33 antigen, which is vital for addressing acute myeloid leukemia (AML) and other myeloid malignancies. Actimab-A utilizes the unique alpha-emitting radioisotope called Actinium-225 (Ac-225) as its payload, showcasing promising results in treating relapsed and refractory AML patients, especially when used in combination with the chemotherapy regimen CLAG-M.

Promising Clinical Results

Recent clinical studies have indicated that Actimab-A has achieved notable success in inducing complete remissions, including instances of measurable residual disease (MRD) negativity. Due to these encouraging outcomes, the therapy is advancing towards a Phase 2/3 clinical trial. Furthermore, the collaboration with the National Cancer Institute (NCI) has led to the initiation of an innovative study under a Cooperative Research and Development Agreement (CRADA). This pioneering trial will assess a triplet combination therapy involving Actimab-A, Venetoclax, and ASTX-727 to benefit frontline AML patients.

Strategic Developments

Beyond Actimab-A, Actinium's portfolio includes Iomab-ACT, which aims to enhance patient access and outcomes in potentially curative cell and gene therapies, and Iomab-B, an agent developed for induction and conditioning before bone marrow transplants in patients facing relapsed and refractory AML. Actinium is currently seeking strategic partnerships in the U.S. to further develop Iomab-B. Additionally, the company is dedicated to advancing several preclinical programs that target solid tumors.

Actinium Pharmaceuticals continues to expand its intellectual property portfolio, holding an impressive number of 230 patents and patent applications, including those concerning the production of Ac-225 in cyclotrons.

Conclusion

With its commitment to innovation and improving patient care through targeted therapies, Actinium Pharmaceuticals is poised to make significant strides in the medical sector. Investors and interested parties attending the Roth Conference will have a unique opportunity to explore the company's developments and future prospects. For further information, you can visit their website at Actinium Pharmaceuticals.

In summary, the participation of Actinium at the Roth Conference marks a pivotal step for the company as it continues to lead the charge in targeted therapies that aim to combat some of the most challenging forms of cancer. It underscores the company’s focus on collaboration, innovation, and commitment to helping patients achieve better outcomes through advanced medical treatments.

• ---